patritumab
daiichi sankyo
['patritumab', 'sclc', 'lcsm,(-blcsm)', 'nsclc']
patritumab deruxtecan induces clinical activity in nsclc regardless of identified driver genomic alterations #asco22 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.